ACTRIMS-ECTRIMS: Ofatumumab Shows Efficacy in New MS Patients
Once-monthly injections allows patients to control their treatment schedule In a group of...
Read MoreOct 16, 2020
Once-monthly injections allows patients to control their treatment schedule In a group of...
Read MoreOct 14, 2020
No overall differences in the functional diversity of the gut microbiome were found in patients with pediatric-onset MS in a study using metagenomic sequencing. However, there were differences in the functional potential...
Read MoreOct 14, 2020
Interim results from two phase 2 studies provide evidence that orally delivered CNM-Au8 (gold nanocrystals) have catalytic effects on key bioenergetic metabolites in the brain of patients with MS and Parkinson’s disease...
Read MoreOct 14, 2020
The presence of cardiovascular (CV) risk factors is associated with brain atrophy in relatively young MS patients under the age of 50. CV risk factors seem to have synergistic effects in MS. CV risk factors have been associated...
Read MoreOct 14, 2020
Long-term efficacy and safety results of eculizumab monotherapy in patients with aquaporin-4 IgG-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during the PREVENT trial and/or its ongoing open-label extension...
Read MoreOct 14, 2020
Most pivotal disease-modifying treatment (DMT) trials miss an opportunity to evaluate and...
Read MoreOct 14, 2020
Cerebrospinal fluid (CSF) tau and beta-amyloid (Aβ) proteins are among the biomarkers currently applied in other neurodegenerative diseases than MS. Partly due to conflicting results, not a single biomarker of axonal damage in...
Read MoreOct 14, 2020
For one of the most prevalent symptoms of MS, fatigue, methylphenidate, modafinil, and amantadine are commonly prescribed. Substantial evidence supporting their efficacy is lacking, however. In the randomized crossover...
Read MoreOct 14, 2020
In an invited lecture, Prof. Xavier Montalban (Vall d’Hebron University Hospital, Barcelona) discussed management of primary and secondary progressive MS (PPMS and SPMS) with approved disease-modifying treatment [1]....
Read MoreOct 14, 2020
An Italian study showed that long-term disability outcomes were more favourable with a strategy of early intensive treatment (EIT) than with moderate-efficacy treatment followed by escalation to higher-efficacy treatment (ESC)....
Read MoreOct 14, 2020
Results of a Spanish two-center study suggest that low doses of rituximab are equally effective as high doses, but have a superior safety profile. The anti-CD20 monoclonal antibody rituximab is not registered for the treatment...
Read MoreOct 14, 2020
Ofatumumab Shows Efficacy & Safety in New MS Patients Only a few weeks prior to MSVirtual2020,...
Read MoreOct 5, 2020
Perspectives from Patrick Vermersch, MD, Professor of Neurology at Lille University in France, and...
Read MoreOct 2, 2020
The interim analysis of the EXCHANGE trial suggest that, for patients with relapsing multiple sclerosis, immediate conversion from oral/injectable disease modifying therapies to siponimod without any washout period (within 24...
Read MoreOct 2, 2020
Neutrophil granulocyte (NG)-specific biomarkers have high sensitivity and specificity for rapid differentiation between acute neuromyelitis optica spectrum disorders (NMOSD), anti-MOG-antibody associated disease (MOGAD), and...
Read MoreOct 2, 2020
During pregnancy and the disease-modifying treatment (DMT)-free postpartum period, serum neurofilament-light (sNfL) levels were augmented [1]. This increase was independent of relapses, suggesting increased subclinical disease...
Read More